



(12) **United States Patent**
Simon et al.

(10) **Patent No.:** **US 8,868,177 B2**
(45) **Date of Patent:** **Oct. 21, 2014**

(54) **NON-INVASIVE TREATMENT OF
NEURODEGENERATIVE DISEASES**

(75) Inventors: **Bruce Simon**, Mountain Lakes, NJ (US);
Joseph P. Errico, Warren, NJ (US);
John T. Raffle, Austin, TX (US)

(73) Assignee: **Electrocore, LLC**, Basking Ridge, NJ
(US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 634 days.

(21) Appl. No.: **13/005,005**

(22) Filed: **Jan. 12, 2011**

(65) **Prior Publication Data**

US 2011/0152967 A1 Jun. 23, 2011

Related U.S. Application Data

(63) Continuation-in-part of application No. 12/964,050,
filed on Dec. 9, 2010, which is a continuation-in-part
of application No. 12/859,568, filed on Aug. 19, 2010,
said application No. 12/859,568 is a
continuation-in-part of application No. 12/408,131,
filed on Mar. 20, 2009.

(60) Provisional application No. 61/415,469, filed on Nov.
19, 2010.

(51) **Int. Cl.**

A61N 1/36 (2006.01)

A61N 2/08 (2006.01)

A61N 1/40 (2006.01)

A61N 2/02 (2006.01)

A61N 2/00 (2006.01)

(52) **U.S. Cl.**

CPC **A61N 1/40** (2013.01); **A61N 1/36114**
(2013.01); **A61N 2/02** (2013.01); **A61N 2/006**
(2013.01)

USPC **607/2**; **607/45**; **600/9**

(58) **Field of Classification Search**

CPC **A61N 2/02**; **A61N 2/006**; **A61N 1/40**;
A61N 1/36114

USPC **607/2**, **45**; **600/9**, **13-15**
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,196,737 A 4/1980 Bevilacqua
4,702,254 A 10/1987 Zabara
4,915,110 A 4/1990 Kitov
5,269,303 A 12/1993 Wernicke et al.

(Continued)

OTHER PUBLICATIONS

Adamson, P. C., et al. Pharmacokinetics of all-trans-retinoic acid
administered on an intermittent schedule. J. Clin. Oncol., 13: 1238-
1241, 1995.

(Continued)

Primary Examiner — Carl H Layno

Assistant Examiner — Jessica Anthony


(74) *Attorney, Agent, or Firm* — Dentons US LLP

(57)

ABSTRACT

Methods and devices for the non-invasive treatment of neu-
rodegenerative diseases through delivery of energy to target
nervous tissue, particularly the vagus nerve. In certain
embodiments, the devices include a magnetic stimulator hav-
ing coils with toroidal windings, which are in contact with an
electrically conducting medium that is adapted to conform to
the contour of a target body surface of a patient. The coils
induce an electric current and/or an electric field within the
patient, thereby stimulating nerve fibers within the patient.
The stimulation brings about reduction of neuroinflammation
in patients suffering from conditions comprising Alzheimer's
Disease, Parkinson's Disease, Multiple Sclerosis, postopera-
tive cognitive dysfunction and postoperative delirium.

60 Claims, 7 Drawing Sheets



(56)

References Cited

U.S. PATENT DOCUMENTS

5,718,662	A	2/1998	Jalinous	
5,766,124	A	6/1998	Polson	
5,903,516	A	5/1999	Greenleaf et al.	
5,983,131	A	11/1999	Weaver et al.	
6,155,966	A	12/2000	Parker	
6,179,770	B1	1/2001	Mould	
6,234,953	B1	5/2001	Thomas et al.	
6,341,236	B1	1/2002	Osorio et al.	
6,527,695	B1	3/2003	Davey et al.	
6,610,713	B2	8/2003	Tracey	
6,701,185	B2 *	3/2004	Burnett et al.	607/2
6,738,667	B2	5/2004	Deno et al.	
6,838,471	B2	1/2005	Tracey	
6,871,099	B1	3/2005	Whitehurst et al.	
7,361,136	B2	4/2008	Parker	
7,396,326	B2	7/2008	Ghiron et al.	
7,614,996	B2	11/2009	Riehl et al.	
7,640,062	B2	12/2009	Shalev	
7,744,523	B2	6/2010	Epstein	
7,769,442	B2	8/2010	Shafer	
2004/0249416	A1	12/2004	Yun et al.	
2005/0075701	A1	4/2005	Shafer	
2005/0075702	A1	4/2005	Shafer	
2005/0125044	A1	6/2005	Tracey	
2005/0216062	A1	9/2005	Herbst	
2005/0261542	A1	11/2005	Riehl	
2006/0030895	A1 *	2/2006	Simon et al.	607/43
2006/0074284	A1	4/2006	Juola et al.	
2006/0178703	A1	8/2006	Huston et al.	
2007/0032827	A1	2/2007	Katims	
2007/0123952	A1	5/2007	Strother et al.	
2007/0150024	A1	6/2007	Leyde et al.	
2007/0167990	A1 *	7/2007	Mangrum et al.	607/40
2007/0276449	A1	11/2007	Gunter et al.	
2008/0071329	A1	3/2008	Giuntoli et al.	
2008/0208266	A1 *	8/2008	Lesser et al.	607/2
2008/0249439	A1	10/2008	Tracey	
2008/0306325	A1	12/2008	Burnett et al.	
2009/0143831	A1	6/2009	Huston	
2009/0248097	A1	10/2009	Tracey	
2009/0281593	A9	11/2009	Errico et al.	
2009/0299435	A1	12/2009	Gliner et al.	
2010/0004716	A1	1/2010	Zimmerling et al.	
2010/0222629	A1	9/2010	Burnett	
2010/0280562	A1	11/2010	Pi	
2011/0046432	A1	2/2011	Simon et al.	

OTHER PUBLICATIONS

Anon. brochure describing Agilent 33522A Function/Arbitrary Waveform Generator, Agilent Technologies, Inc., 5301 Stevens Creek Blvd Santa Clara CA 95051.

Anonymous. TNF neutralization in MS: Results of a randomized, placebo controlled multicenter study. *Neurology* 1999, 53:457.

Arnett Ha, et al. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. *Nat Neurosci* 2001, 4:1116-1122.

Baumgartner, et al. Constitutive and inducible mechanisms for synthesis and release of cytokines in immune cell lines. *The Journal of Immunology* 157 (1996, 9): 4087-4093.

Biggio F, et al. Chronic vagus nerve stimulation induces neuronal plasticity in the rat hippocampus. *Int J Neuropsychopharmacol.* 12(9,2009):1209-21.

Bittar, R.G. Neuromodulation for movement disorders. *J. Clin. Neurosci.* 13 (2006), 315-318.

Bokkala-Pinninti, et al. Vagus nerve stimulation effective for focal motor seizures and focal interictal parkinsonian symptoms—A case report. *Journal of Neurology* 255(2008,2): 301-302.

Braak et al. Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. *Mov Disord* 21(12,2006):2042-51.

Camacho I. et al. Peroxisome-proliferator-activated receptor gamma

Castren et al. Light regulates expression of brain-derived neurotrophic factor mRNA in rat visual cortex. *Proc. Nat. Acad. Sci. USA* 89 (1992): 9444-9448.

Chan et al. (2007) 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. *Nature* 447: 1081-1086.

Corcoran et al. The effects of vagus nerve stimulation on pro- and anti-inflammatory cytokines in humans: a preliminary report. *Neuroimmunomodulation* 12 (5, 2005): 307-309.

Czura Cj et al. Autonomic neural regulation of immunity. *J Intern Med.* 257(2005, 2): 156-66.

Follesa P et al. Vagus nerve stimulation increases norepinephrine concentration and the gene expression of BDNF and bFGF in the rat brain. *Brain Research* 1179(2007): 28-34.

Fregni et al. Non-invasive brain stimulation for Parkinson's disease: a systematic review and meta-analysis of the literature. *J Neurol Neurosurg Psychiatry* 2005;76:1614-1623.

Friling et al. Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease. *BMC Neuroscience* 2009, 10:146.

Garcia, L. et al. High-frequency stimulation in Parkinson's Disease: More or less? *Trends Neurosci.* 2005 28, 209-216.

Goetz et al. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results. *Movement Disorders* 23 (No. 15, 2008): 2129-2170.

Graeber. Biomarkers for Parkinson's disease. *Experimental Neurology* 216 (2009) 249-253.

Jankovic. Parkinson's disease: clinical features and diagnosis. *J Neurol Neurosurg Psychiatry* 79(2008):368-376.

Kriegstein. Factors promoting survival of mesencephalic dopaminergic neurons. *Cell Tissue Res* (2004) 318: 73-80.

Landau et al. Athanasios P Zis and Doris J Doudet. Electroconvulsive Therapy Alters Dopamine Signaling in the Striatum of Non-human Primates. *Neuropsychopharmacology*, (Oct. 13, 2010, Epub ahead of print).

Lefaucheur, J.P. et al. 2004. Improvement of motor performance and modulation of cortical excitability by repetitive transcranial magnetic stimulation of the motor cortex in Parkinson's Disease. *Clin. Neurophysiol.* 115, 2530-2541.

Maden. Retinoic acid in the development, regeneration and maintenance of the nervous system. *Nature Reviews Neuroscience* 8(2007), 755-765.

Malaspina et al. Is the modulation of retinoid and retinoid associated signaling a future therapeutic strategy in neurological trauma and neurodegeneration? *J. Neurochem.* (2008) 104, 584-595.

McCoy et al. Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease. *The Journal of Neuroscience* 26(37,2006):9365-9375.

Mey et al. Retinoic Acid Signaling in the Nervous System of Adult Vertebrates. *The Neuroscientist* 10(5, 2004): 409-421.

Michell et al. Biomarkers and Parkinson's disease. *Brain* (2004), 127, 1693-1705.

Mucida D et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. *Science* 317(2007, 5835): 256-60.

Nagahara et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. *Nat Med.* 15(3,2009): 331-337.

Obeso et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. *Mov. Disord.* 23 (Suppl 3,2008): S548-59.

Pan, Seiji Kondo, Weidong Le, Joseph Jankovic. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. *Brain* 131 (2008): 1969-1978.

Paus et al. Bright Light Therapy in Parkinson's Disease: A Pilot Study. *Movement Disorders* 22(10, 2007): 1495-1498.

Pavlov et al. Controlling inflammation: the cholinergic anti-inflammatory pathway. *Biochemical Society Transactions* 34, (2006, 6): 1037-1040.

Saijo et al. A Nurr1/CoREST Pathway in Microglia and Astrocytes

(56)

References Cited**OTHER PUBLICATIONS**

- Shin, J.-H. et al. SnapShot: Parkinson's disease pathogenesis. *Cell* 139 (2009):440-440.
- Shudo, H. et al. Towards Retinoid Therapy for Alzheimer's Disease. *Current Alzheimer Research*, 2009, 6, 302-311.
- Tafti et al. Functional Implication of the Vitamin A Signaling Pathway in the Brain. *Arch Neurol*. 64(12,2007): 1706-1711.
- Tuszynski. Nerve Growth Factor Gene Therapy in Alzheimer Disease. *Alzheimer Dis Assoc Disord* 21 (2, 2007): 179-189.
- van de Pavert et al. Chemokine CXCL13 is essential for lymph node initiation and is induced by retinoic acid and neuronal stimulation. *Nat Immunol*. 10(11, 2009): 1193-1199.
- Vincent Va. et al. Inhibition of endotoxin-induced nitric oxide synthase production in microglial cells by the presence of astroglial cells: a role for transforming growth factor beta. *Glia*. 19(3,1997):190-8.
- Voutilainen MH et al. Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Neurorestorative in Rat Model of Parkinson's Disease. *The Journal of Neuroscience*, Jul. 29, 2009, 29(30):9651-9659.
- Wyss-Coray. TGF-beta Pathway as a Potential Target in Neurodegeneration and Alzheimer's. *Current Alzheimer Research*, 3(2006): 191-195.
- Xiao et al. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF- β -driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. *J Immunol*. 181(2008, 4): 2277-2284.
- Zanardini et al. Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. *Journal of Affective Disorders* 91 (2006) 83-86.
- Albert, et al. Deep brain stimulation, vagal nerve stimulation and transcranial stimulation: An overview of stimulation parameters and neurotransmitter release. *Neuroscience and Biobehavioral Reviews* 33 (2009) 1042-1060.
- Al-Mutawaly, et al. The Effects of Pulse Configuration on Magnetic Stimulation. *Journal of Clinical Neurophysiology* 20(5):361-370, 2003.
- Amor, et al. Inflammation in neurodegenerative diseases. *Immunology*, 129 (2010), 154-169.
- Anderson, et al. Decreasing Procedural Pain Over Time of Left Prefrontal rTMS for Depression: Initial Results from the Open-Label Phase of a Multisite Trial (OPT-TMS). *Brain Stimul*. Apr. 1, 2009; 2(2): 88-92.
- Aziz et al. Magnetic Stimulation of Efferent Neural Pathways to the Human Oesophagus. *Gut* 33: S53-S70 (Poster Session F218) (1992).
- Aziz, Q. et al. Esophageal myoelectric responses to magnetic stimulation of the human cortex and the extracranial vagus nerve. *Am. J. Physiol*. 267 (Gastrointest. Liver Physiol. 30): G827-G835, 1994.
- Basham, et al. Magnetic Stimulation of Neural Tissue: Techniques and System Design. pp. 293-352, In: *Implantable Neural Prostheses I, Devices and Applications*, D. Zhou and E. Greenbaum, eds., New York: Springer (2009).
- Borckardt, et al. Reducing Pain and Unpleasantness During Repetitive Transcranial Magnetic Stimulation. *Journal of ECT* 2006; 22:259-264.
- Bowtell et al. Analytic Calculations of the E-Fields Induced by Time-Varying Magnetic Fields Generated by Cylindrical Gradient Coils. *Magnetic Resonance in Medicine* 44:782-790 (2000).
- Bredesen, et al. Cell death in the nervous system. *Nature* 443(2006): 796-802.
- Cameron, MH, et al. Transcutaneous Electrical Nerve Stimulation (TENS) for dementia. *Cochrane Database of Systematic Reviews* 2003, Issue 3. Art. No. CD004032. (2009 update).
- Carbunaru et al. Toroidal coil models for transcutaneous magnetic stimulation of nerves. *IEEE Transactions on Biomedical Engineering*. 48 (No. 4, Apr. 2001): 434-441.
- Faierstein et al. Coil Designs for Localized and Efficient Magnetic Stimulation of the Nervous System. Ph.D. Dissertation, Department
- Chae et al. A review of functional neuroimaging studies of vagus nerve stimulation (VNS). *Journal of Psychiatric Research* 37 (2003) 443-455.
- Chang et al. Prevalence and risk factors for postoperative delirium in a cardiovascular intensive care unit. *American Journal of Critical Care*. 2008;17:567-575.
- Choileain et al. Cell response to surgery. *Arch Surg* 2006; 141:1132-40.
- Chou, Michael A. et al. Tumor Necrosis Factor Inhibition Reduces the Incidence of Alzheimer's Disease in Rheumatoid Arthritis Patients. Program abstracts of the American College of Rheumatology/Association of Rheumatology Health Professionals Scientific Meeting, Nov. 8, 2010, Atlanta GA, Presentation No. 640.
- Clark et al. The roles of TNF in brain dysfunction and disease. *Pharmacology & Therapeutics*, 128 (Issue 3, Dec. 2010): 519-548.
- Compston et al. Multiple sclerosis. *Lancet* 372 (9648, Oct. 2008): 1502-1517.
- Cotelli M et al. Transcranial magnetic stimulation improves naming in Alzheimer disease patients at different stages of cognitive decline. *Eur J Neurol*. 15(12, 2008):1286-92.
- Data sheet for Right Guard Clear Gel from Dial Corporation, 15501 N. Dial Boulevard, Scottsdale AZ 85260.
- Data sheet for Tecophlic from the Lubrizol Corporation, 29400 Lakeland Boulevard, Wickliffe, Ohio 44092.
- Davey. Magnetic Stimulation Coil and Circuit Design. *IEEE Transactions on Biomedical Engineering*, vol. 47 (No. 11, Nov. 2000): 1493-1499.
- Hsu KH, Nagarajan SS, Durand DM. Analysis of efficiency of magnetic stimulation. *IEEE Trans Biomed Eng*. Nov. 2003; 50 (11):1276-85.
- Delegge. Neurodegeneration and Inflammation. *Nutrition in Clinical Practice* 23 (2008):35-41.
- Delitto et al. A Study of Discomfort with Electrical Stimulation. *Phys. Ther*. 1992; 72:410-424.
- Esselle et al. Neural stimulation with magnetic fields: Analysis of induced electric fields, *IEEE Trans. Biomed. Eng.*, 39 (Jul. 1992), pp. 693-700.
- Marrosu et al. Vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. *Multiple Sclerosis* 2007; 13: 1200-1202.
- Feynman et al. *The Feynman Lectures on Physics*. vol. II. Addison-Wesley Publ. Co. (Reading MA, 1964), p. 15-15.
- Fricchione et al. Postoperative Delirium. *Am J Psychiatry* 165 (Jul. 7, 2008): 803-812.
- George et al. Mechanisms of action of vagus nerve stimulation (VNS). *Clinical Neuroscience Research* 4 (2004) 71-79.
- Glass et al. Mechanisms Underlying Inflammation in Neurodegeneration. *Cell* 140 (2010): 918-934.
- Green et al. Conducting polymer-hydrogels for medical electrode applications. *Sci. Technol. Adv. Mater*. 11 (2010) 014107 (13pp).
- Griffin. Perispinal etanercept: Potential as an Alzheimer therapeutic. *Journal of Neuroinflammation* 2008, 5:3.
- Tobinick. Tumor Necrosis Factor Modulation for Treatment of Alzheimer's Disease Rationale and Current Evidence. *CNS Drugs* 2009; 23 (9): 713-725.
- Groves et al. Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects. *Neurosci Biobehav Rev* (2005) 29:493-500.
- Guse B et al. Cognitive effects of high-frequency repetitive transcranial magnetic stimulation: a systematic review. *J Neural Transm*. 117(1,2010):105-22.
- Haass. Initiation and propagation of neurodegeneration. *Nature Medicine* 16(11,2010): 1201-1204.
- Hafler DA, Kent SC, Pietrusiewicz MJ, Khoury SJ, Weiner HL and Fukaura H. Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. *Ann NY Acad Sci* 1997;56:120-131.
- Hakkinen et al. Which structures are sensitive to painful transcranial stimulation? *Electromyogr. clin. Neurophysiol*. 1995, 35:377-383.
- Hala. Pathophysiology of postoperative delirium: Systemic inflam-

(56)

References Cited**OTHER PUBLICATIONS**

Hamdy et al. Long-term reorganization of human motor cortex driven by short-term sensory stimulation. *Nature Neuroscience* 1 (issue 1, May 1998):64-68.

Hamdy et al. Cranial nerve modulation of human cortical swallowing motor pathways. *Am. J. Physiol.* 272 (Gastrointest. Liver Physiol. 35): G802-G808, 1997.

Heimburg et al. On soliton propagation in biomembranes and nerves. *PNAS* vol. 102 (No. 28, Jul. 12, 2005): 9790-9795.

Hovey et al. *The Guide to Magnetic Stimulation*, The Magstim Company Ltd, Spring Gardens, Whitland, Carmarthenshire, SA34 0HR, United Kingdom, 2006.

Hu et al. Inflammation: a bridge between postoperative cognitive dysfunction and Alzheimer's disease. *Med Hypotheses*. Apr. 2010;74(4):722-4.

Johnston et al. Cytokines and the immunomodulatory function of the vagus nerve. *British Journal of Anaesthesia* 102(4,2009): 453-462.

Ketelaer et al. Percutaneous epidural dorsal cord stimulation in multiple sclerosis. *Acta Neurochirurgica* 49 (1979): 95-101.

Khedr et al. Aref Electrophysiological study of vocal-fold mobility disorders using a magnetic stimulator. *European Journal of Neurology* 2002, 9: 259-267.

Khedr et al. Dysphagia and hemispheric stroke: A transcranial magnetic study. *Neurophysiologie Clinique/Clinical Neurophysiology* (2008) 38, 235-242).

Kim YS, et al. major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. *Exp Mol Med* 38(2006): 333-347.

Krause P. et al. FES cycling reduces spastic muscle tone in a patient with multiple sclerosis. *NeuroRehabilitation*. 2007;22(4):335-7.

Lang AE. Et al. Parkinson's disease. Second of two parts. *N Engl J Med* 339 (No. 16,1998): 1130-1143.

Levy, et al. Therapeutic Potential of Neurotrophic Factors in Neurodegenerative Diseases. *Biodrugs* 2005; 19 (2): 97-127.

Liboff. Signal shapes in electromagnetic therapies: a primer. pp. 17-37 in: *Bioelectromagnetic Medicine* (Paul J. Rosch and Marko S. Markov, eds.), New York: Marcel Dekker (2004).

Lin et al. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. *Nature* 443(2006): 787-795.

Liu et al. On the Induced Electric Field Gradients in the Human Body for Magnetic Stimulation by Gradient Coils in MRI, *IEEE Transactions on Biomedical Engineering* 50: (No. 7, Jul. 2003) pp. 804-815.

Lo. Degeneration and repair in central nervous system disease. *Nature Medicine* 16(11,2010):1205-1209.

Makar et al. Brain derived neurotrophic factor treatment reduces inflammation and apoptosis in experimental allergic encephalomyelitis. *J Neurol Sci.* 270(1-2,2008):70-6.

Man et al. Magnetic stimulation for the measurement of respiratory and skeletal muscle function. *Eur Respir J* 2004; 24: 846-860.

Mangialasche F. et al. Alzheimer disease: clinical trials and drug development. *Lancet Neurol.* Jul. 2010;9(7):702-16.

Marrosu, A. et al. Vagal nerve stimulation effects on cerebellar tremor in multiple sclerosis. *Neurology* 65 (2005): 490.

McCoy et al. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. *Journal of Neuroinflammation* 2008, 5:45.

Merrill CA et al. Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year. *J Clin Psychiatry.* Aug. 2006;67(8):1 171-8.

Mirshafiey A et al. TGF-beta as a promising option in the treatment of multiple sclerosis. *Neuropharmacology* 56(6-7, 2009):929-36.

Nilsson et al. Determining the site of stimulation during magnetic stimulation of the peripheral nerve, *Electroencephalographs and clinical neurophysiology*. vol. 85, pp. 253-264, 1992.

Olney et al. A comparison of magnetic and electric stimulation of peripheral nerves. *Muscle Nerve* 1990;13:957-963.

Patent application JP2008/081479A (Publication No. JP2009233024A), entitled Vagus nerve stimulation system, to Yoshihito.

Peck. IADRD: Pilot Study of Thalidomide for Alzheimer's Disease Fails to Detect Cognitive Benefit but Finds Effect on TNF-alpha. *Doctor's Guide Global Edition*, Jul. 26, 2002.

Perea et al. GLIA modulates synaptic transmission. *Brain Research Reviews*. 63 (Issues 1-2, May 2010):93-102.

Perry. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. *Brain, Behavior, and Immunity* 18 (2004): 407-413.

Polak T. et al. Far field potentials from brain stem after transcutaneous vagus nerve stimulation: optimization of stimulation and recording parameters. *J Neural Transm.* Oct. 2009; 116(10):1237-42.

Prolo et al. Putative NeuroImmune Mechanisms in Alzheimer's Disease: Modulation by Cholinergic Anti-Inflammatory Reflex (CAIR). *International Journal of Integrative Biology* 2007, vol. 1 (No. 2):88-95.

Rafferty et al. Magnetic phrenic nerve stimulation to assess diaphragm function in children following liver transplantation. *Pediatr Crit Care Med* 2001, 2:122-126.

Ramaiah et al. Postoperative Cognitive Dysfunction in the Elderly. *Anesthesiology Clin* 27(2009): 485-496.

Rasmussen. Postoperative cognitive dysfunction: Incidence and prevention. *Best Practice & Research Clinical Anaesthesiology* 20(2006, No. 2): 315-330.

Rattay. The basic mechanism for the electrical stimulation of the nervous system. *Neuroscience* vol. 89, No. 2, pp. 335-346, 1999.

Rudolph et al. Chemokines are Associated with Delirium after Cardiac Surgery. *J Gerontol A Biol Sci Med Sci.* Feb. 2008 63(2): 184-189.

Rudra A. et al. Postoperative delirium. *Indian J Crit Care Med* 2006;10:235-40.

Sauer et al. Postoperative cognitive decline. *J Anesth* (2009) 23:256-259.

Sawicki et al. Mathematical Modelling of Vagus Nerve Stimulation. pp. 92-97 in: Krawczyk, A. *Electromagnetic Field, Health and Environment: Proceedings of EHE'07*. Amsterdam, IOS Press, 2008.

Schultzberg et al. Inflammation in the nervous system—Physiological and pathophysiological aspects. *Physiology & Behavior* 92 (2007) 121-128.

Selnes et al. Neurocognitive Complications after Coronary Artery Bypass Surgery. *Ann Neurol* 2005;57:615-621.

Shafik, A. Functional magnetic stimulation of the vagus nerve enhances colonic transit time in healthy volunteers. *Tech Coloproctol* (1999) 3:123-12.

Similowski, T. et al. Cervical magnetic stimulation: a new painless method for bilateral phrenic nerve stimulation in conscious humans. *J. Appl. Physiol.* 67(4): 1311-1318,1989.

Sims et al. Assessing the clinical utility of the magnetic stimulator for measuring response latencies in the laryngeal muscles. *Otolaryngol Head Neck Surg* 1996; 114:761-7.

Sjogren et al. Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: a pilot study. *J Clin Psychiatry.* Nov. 2002;63(11):972-80.

Skovronsky et al. Neurodegenerative Diseases: New Concepts of Pathogenesis and Their Therapeutic Implications. *Annu. Rev. Pathol. Mech. Dis.* 1(2006): 151-70.

Smith et al. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. *Philos Trans R Soc Lond B Biol Sci.* Oct. 29, 1999; 354(1390): 1649-1673.

Stuchbury G. et al. Alzheimer associated inflammation, potential drug targets and future therapies. *J Neural Transm.* Mar. 2005; 112(3):429-53.

Suihko. Modelling the response of scalp sensory receptors to transcranial electrical stimulation. *Med. Biol. Eng. Comput.*, 2002,40,395-401.

Terry, Jr. Vagus nerve stimulation: a proven therapy for treatment of

(56)

References Cited**OTHER PUBLICATIONS**

The web site (www) of the National Institute of Neurological Disorders and Stroke (ninds) of the National Institutes of Health (nih) of the United States government (gov) in a subdirectory (/disorders/disorder_index) web page (htm).

Tobinick et al. Rapid cognitive improvement in Alzheimer disease following perispinal etanercept administration. *Journal of Neuroinflammation* 2008, 5:2.

Tracey. Physiology and immunology of the cholinergic antiinflammatory pathway. *J. Clin. Invest.* 117(2007): 289-296.

Tracey. The inflammatory reflex. *Nature* 420(2002): 853-859.

Tracey. Understanding immunity requires more than immunology. *Nature Immunology* 11(2010): 561-564.

Tweedie D. et al. TNF-alpha Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets. *Curr Alzheimer Res* 2007, 4(4):375-8.

Wan et al. Postoperative impairment of cognitive function in rats: a possible role for cytokine-mediated inflammation in the hippocampus. *Anesthesiology* 2007; 106:436-43.

Wang et al. A three-dimensional finite element method for computing magnetically induced currents in tissues. *IEEE Transactions on Magnetics*. 30 (Nov. 6, 1994): 5015-5023.

www.ninds.nih.gov/disorders/disorder_index.htm.

Xie GL et al. Relationship between perioperative inflammatory response and postoperative cognitive dysfunction in the elderly. *Med Hypotheses* 2009;73:402-3.

Xiong J et al. Transcutaneous vagus nerve stimulation may attenuate postoperative cognitive dysfunction in elderly patients. *Medical Hypotheses* 73 (2009) 938-941.

Zipp et al. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. *Trends in Neurosciences* 29 (9, 2006) 518-527.

International Search Report and Written Opinion of the International Searching Authority dated Dec. 3, 2011, PCT application PCT/US11/47509, International Filing Date Aug. 12, 2011.

International Search Report and Written Opinion of the International Searching Authority dated Dec. 22, 2011, PCT application PCT/US11/49844, International Filing Date Aug. 30, 2011.

* cited by examiner

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.